Investigational drug · Phase 2
NS101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Seneorineural Deafness, Sudden Sensorineural Hearing Loss.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "NS101"
First trial start
2024
Feb 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NS101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Seneorineural Deafness
- Sudden Sensorineural Hearing Loss
Largest trials
Live from ClinicalTrials.gov: studies naming "NS101" as an intervention, largest first.
- A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL PatientsPivotal-lookingCompleted
Neuracle Science Co., LTD.Industry
NCT06249919 · 113 participants · Start Feb 15, 2024 · Primary completion May 4, 2026
Drug: NS101; Placebo · For: Seneorineural Deafness; Sudden Sensorineural Hearing Loss
Sites: Bucheon-si, South Korea; Changwon, South Korea; Daegu, South Korea · 15 sites in all
Neuracle Science Co., LTD.Industry
NCT05143463 · 64 participants · Start Nov 4, 2021 · Primary completion Aug 19, 2022
Drug: NS101 IV infusion · For: Neurodegenerative Diseases
Sites: Québec, Canada
- Investigator Initiated Study for the Safety and Efficacy in Frontotemporal DementiaNot yet recruiting
Hee-Jin KimAcademic, hospital or other
NCT07154485 · 15 participants (planned) · Start Oct 1, 2025 · Primary completion Aug 1, 2027
Drug: NS101 IV infusion; Placebo IV Infusion · For: Dementia Frontotemporal
Newest research
PubMed records naming it or its code names, newest first.
- Inhibition of FAM19A5 reverses synaptic loss and cognitive decline in mouse models of Alzheimer's disease.
Kim HB, Yoo S, Kwak H, et al. · Alzheimers Res Ther 2025
- Novel Ehrlichia sp. detected in Magellanic penguins (Sphenicus magellanicus) and in the seabird tick Ixodes uriae from Magdalena Island, southern Chile.
Muñoz-Leal S, Clemes YS, Lopes MG, et al. · Ticks Tick Borne Dis 2019
- [Phase I study of intrathecal chemotherapy with NS-101 for leptomeningeal carcinomatosis in Japan].
Nakagawa H, Tamura M, Fukushima Y, et al. · Gan To Kagaku Ryoho 2007
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.